Serbia reaches a milestone for influenza vaccines manufacturing

Institute for Virology, Vaccines and Serums “Torlak”

On April 25, 2018, a meeting was held in Belgrade, Serbia to celebrate the successful development of a seasonal inactivated trivalent influenza vaccine by the Institute of Virology, Vaccines and Sera (Torlak).

The project was started in 2009 as part of the Global Action Plan for Influenza Vaccines (GAP) – initiated by WHO in 2006 to reduce the global shortage of influenza vaccines – and was supported by investments from the Serbian government, PATH, the United Biomedical Advanced Research and Development Authority (BARDA), Torlak and WHO.

In addition to Serbia, WHO and its partners have supported 13 other low- and middle-income countries in building production capacity for influenza vaccines, with the ultimate goal that in the event of a pandemic, countries with sustainable production capacity for seasonal influenza could switch to pandemic influenza vaccine production for domestic and regional / international supply.

With the newly established production capacity for influenza vaccines, Serbia has the potential to become a regional supply center for seasonal and pandemic influenza vaccines. Continuous investment over the coming years is critical to maintaining and expanding Torlak’s facilities to maintain and increase dose production capacity.

Comments are closed.